

BILL SUMMARY
1st Session of the 59th Legislature

Bill No.:	SB513
Version:	ENGR
Request Number:	
Author:	Rep. Miller
Date:	4/5/2023
Impact:	See Below

Research Analysis

The engrossed version of SB 513 requires that each health benefit plan provide coverage for biomarker testing and documented evidence of such coverage including:

- Labeled indications for tests that are approved or cleared by the United States Food and Drug Administration (FDA).
- Tests for a drug that is approved by the FDA.
- Precautions on FDA approved drug labels.
- National coverage determinations or Medicare administrative contractor local coverage determinations.
- Nationally recognized clinical practice guidelines and consensus statements.

The measure also requires that the insured have access to a clear, readily available, and convenient process to request an exception to a coverage policy of a health benefit plan.

Prepared By: Matthew Brenchley

Fiscal Analysis

In its current form, SB513 requires that health benefit plans provide coverage for biomarker testing and documented evidence of such coverage. Officials from the Office of Management and Enterprise Services estimate that the annual impact of this change is less than \$500,000, or a 0.05% increase in total premium.

Prepared By: Zachary Penrod, House Fiscal Staff

Other Considerations

None.